These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

261 related items for PubMed ID: 18268287

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab.
    Lindén O, Hindorf C, Cavallin-Ståhl E, Wegener WA, Goldenberg DM, Horne H, Ohlsson T, Stenberg L, Strand SE, Tennvall J.
    Clin Cancer Res; 2005 Jul 15; 11(14):5215-22. PubMed ID: 16033839
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. FDG PET and 90Y ibritumomab tiuxetan in patients with follicular lymphoma.
    Lopci E, Santi I, Tani M, Maffione AM, Montini G, Castellucci P, Stefoni V, Rubello D, Fonti C, Zinzani P, Fanti S.
    Q J Nucl Med Mol Imaging; 2010 Aug 15; 54(4):436-41. PubMed ID: 20823812
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. 18F-FDG PET/CT for monitoring the response of lymphoma to radioimmunotherapy.
    Jacene HA, Filice R, Kasecamp W, Wahl RL.
    J Nucl Med; 2009 Jan 15; 50(1):8-17. PubMed ID: 19091903
    [Abstract] [Full Text] [Related]

  • 9. Use of ibritumomab tiuxetan anti-CD20 radioimmunotherapy in a non-Hodgkin's lymphoma patient previously treated with a yttrium-90-labeled anti-CD22 monoclonal antibody.
    Tsai DE, Maillard I, Schuster SJ, Nasta SD, Porter DL, Klumpp TR, Goldenberg DM, Luger SM, Alavi A, Sharkey RM, Hartzell KB, Stadtmauer EA.
    Clin Lymphoma; 2003 Jun 15; 4(1):56-9. PubMed ID: 12837157
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma.
    Morschhauser F, Kraeber-Bodéré F, Wegener WA, Harousseau JL, Petillon MO, Huglo D, Trümper LH, Meller J, Pfreundschuh M, Kirsch CM, Naumann R, Kropp J, Horne H, Teoh N, Le Gouill S, Bodet-Milin C, Chatal JF, Goldenberg DM.
    J Clin Oncol; 2010 Aug 10; 28(23):3709-16. PubMed ID: 20625137
    [Abstract] [Full Text] [Related]

  • 13. Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography.
    Juweid ME, Wiseman GA, Vose JM, Ritchie JM, Menda Y, Wooldridge JE, Mottaghy FM, Rohren EM, Blumstein NM, Stolpen A, Link BK, Reske SN, Graham MM, Cheson BD.
    J Clin Oncol; 2005 Jul 20; 23(21):4652-61. PubMed ID: 15837965
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma.
    Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, Rigo P, Fillet G.
    Haematologica; 2000 Jun 20; 85(6):613-8. PubMed ID: 10870118
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
    Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, Pohlman BL, Bartlett NL, Wiseman GA, Padre N, Grillo-López AJ, Multani P, White CA.
    J Clin Oncol; 2002 May 15; 20(10):2453-63. PubMed ID: 12011122
    [Abstract] [Full Text] [Related]

  • 18. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging.
    Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, Rigo P, Fillet G.
    Blood; 1999 Jul 15; 94(2):429-33. PubMed ID: 10397709
    [Abstract] [Full Text] [Related]

  • 19. Early therapy monitoring with FDG-PET in aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma.
    Torizuka T, Nakamura F, Kanno T, Futatsubashi M, Yoshikawa E, Okada H, Kobayashi M, Ouchi Y.
    Eur J Nucl Med Mol Imaging; 2004 Jan 15; 31(1):22-8. PubMed ID: 14574514
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.